Mechanistic Studies Division, Environmental and Radiation Health Sciences Directorate, HECSB, Health Canada, Ottawa, ON, Canada.
Environ Mol Mutagen. 2011 Dec;52(9):756-65. doi: 10.1002/em.20688. Epub 2011 Oct 4.
In this study we compared the response of the Pig-a gene mutation assay to that of the lacZ transgenic rodent mutation assay, and demonstrated that multiple endpoints can be measured in a 28-day repeat dose study. Muta™Mouse were dosed daily for 28 days with benzo[a]pyrene (BaP; 0, 25, 50 and 75 mg/kg body weight/day) by oral gavage. Micronucleus (MN) frequency was determined in reticulocytes (RETs) 48 hr following the last dose. 72 h following the last dose, mice were euthanized, and tissues (glandular stomach, small intestine, bone marrow and liver) were collected for lacZ mutation and DNA adduct analysis, and blood was evaluated for Pig-a mutants. BaP-derived DNA adducts were detected in all tissues examined and significant dose-dependent increases in mutant Pig-a phenotypes (i.e., RET(CD24-) and RBC (CD24-)) and lacZ mutants were observed. We estimate that mutagenic efficiency (i.e., rate of conversion of adducts into mutations) was much lower for Pig-a compared to lacZ, and speculate that this difference is likely explained by differences in repair capacity between the gene targets, and differences in the cell populations sampled for Pig-a versus lacZ. The BaP doubling doses for both gene targets, however, were comparable, suggesting that similar mechanisms are involved in the accumulation of gene mutations. Significant dose-related increases in % MN were also observed; however, the doubling dose was considerably higher for this endpoint. The similarity in dose response kinetics of Pig-a and lacZ provides further evidence for the mutational origin of glycosylphosphatidylinositol (GPI)-anchor deficiencies detected in the Pig-a assay.
在这项研究中,我们比较了 Pig-a 基因突变检测与 lacZ 转基因啮齿动物突变检测的反应,证明在 28 天重复剂量研究中可以测量多个终点。Muta™Mouse 通过口服灌胃每天接受苯并[a]芘(BaP;0、25、50 和 75 mg/kg 体重/天)处理 28 天。最后一次给药后 48 小时测定网织红细胞(RETs)中的微核(MN)频率。最后一次给药后 72 小时,处死小鼠,收集组织(胃腺、小肠、骨髓和肝脏)进行 lacZ 突变和 DNA 加合物分析,并评估血液中的 Pig-a 突变体。在所有检查的组织中均检测到 BaP 衍生的 DNA 加合物,并观察到突变 Pig-a 表型(即 RET(CD24-)和 RBC(CD24-))和 lacZ 突变体显著剂量依赖性增加。我们估计 Pig-a 的诱变效率(即,加合物转化为突变的速率)比 lacZ 低得多,并且推测这种差异可能是由于基因靶标之间的修复能力差异以及用于 Pig-a 与 lacZ 的细胞群体差异所致。然而,两种基因靶标的 BaP 加倍剂量相当,这表明相似的机制参与了基因突变的积累。还观察到 MN 的 %显著剂量相关增加;然而,该终点的加倍剂量要高得多。Pig-a 和 lacZ 的剂量反应动力学相似,这进一步证明了在 Pig-a 检测中检测到的糖基磷脂酰肌醇(GPI)锚缺失的突变起源。